|
|
 Previous Article | Table of Contents | Next Article 
Concentrations of Thrombopoietin in Bone Marrow in Normal Subjects
and in Patients With Idiopathic Thrombocytopenic Purpura, Aplastic
Anemia, and Essential Thrombocythemia Correlate With Its mRNA
Expression of Bone Marrow Stromal Cells
Yasuo Hirayama,
Sumio Sakamaki,
Takuya Matsunaga,
Takashi Kuga,
Hiroyuki Kuroda,
Toshiro Kusakabe,
Katsunori Sasaki,
Koshi Fujikawa,
Junji Kato,
Katsuhisa Kogawa,
Ryuzo Koyama, and
Yoshiro Niitsu
From the 4th Department of Internal Medicine, Sapporo Medical
University School of Medicine, Sapporo, Japan; and Hokkaido Prefectural
Sapporo Kitano Hospital, Sapporo, Japan.
The function of bone marrow (BM) stromal thrombopoietin (TPO) in
megakaryopoiesis remains unknown. In the present study we attempted to
clarify the pathophysiological implications of stromal TPO in normal
subjects (NS) and in patients with idiopathic thrombocytopenic purpura
(ITP), aplastic anemia (AA), and essential thrombocythemia (ET) by
measuring TPO concentrations in BM and peripheral blood (PB) and by
estimating the levels of stromal TPO mRNA with TaqMan fluorescence-based post-reverse transcription-polymerase chain reaction product detection system. The results showed that TPO concentrations in PB were significantly elevated in patients with ITP
(34.9 ± 11.7 pg/mL) and AA (364.1 ± 153.5 pg/mL) but within normal
range in patients with ET (each 20.0 and 22.1; NS, 22.1 ± 8.2 pg/mL).
In all subjects, the TPO concentrations in BM correlated well with the
PB levels, and the former were consistently higher than the latter. The
concentrations of TPO in BM also correlated with the levels of TPO mRNA
in stromal cells. Furthermore, expression levels of TPO mRNA clearly
correlated with megakaryocyte counts in NS and patients with ITP,
indicating that stromal TPO actually enhances megakaryopoiesis. Thus,
our results in the present study indicate that TPO from BM stromal
cells is considered to play an essential role for megakaryopoiesis
under various patho-physiological conditions.
Blood, Vol. 92 No. 1 (July 1), 1998:
pp. 46-52
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Kawano, M. Kobune, M. Yamaguchi, K. Nakamura, Y. Ito, K. Sasaki, S. Takahashi, T. Nakamura, H. Chiba, T. Sato, et al.
Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells
Blood,
January 15, 2003;
101(2):
532 - 540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mouzaki, M. Theodoropoulou, I. Gianakopoulos, V. Vlaha, M.-C. Kyrtsonis, and A. Maniatis
Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis
Blood,
August 13, 2002;
100(5):
1774 - 1779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ando, Y. Iwamoto, A. Suda, K. Tsuchiya, and H. Nihei
New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels
Blood,
February 15, 2001;
97(4):
915 - 921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Axelrad, D. Eskinazi, P. N. Correa, and D. Amato
Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia
Blood,
November 15, 2000;
96(10):
3310 - 3321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. SATO, N. YAMAUCHI, M. TAKAHASHI, K. SASAKI, J. FUKAURA, H. NEDA, S. FUJII, M. HIRAYAMA, Y. ITOH, Y. KOSHITA, et al.
In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate
FASEB J,
October 1, 2000;
14(13):
2108 - 2118.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. N. Schwartz, U. Kammula, M. K. Warren, M. K. Park, X.-Y. Yan, F. M. Marincola, and R. E. Gress
Thrombopoietin and Chemokine mRNA Expression in Patient Post-Chemotherapy and In Vitro Cytokine-Treated Marrow Stromal Cell Layers
Stem Cells,
September 1, 2000;
18(5):
331 - 342.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Solanilla, J. Dechanet, A. El Andaloussi, M. Dupouy, F. Godard, J. Chabrol, P. Charbord, J. Reiffers, A. T. Nurden, B. Weksler, et al.
CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells
Blood,
June 15, 2000;
95(12):
3758 - 3764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Muto, M. D. Feese, Y. Shimada, Y. Kudou, T. Okamoto, T. Ozawa, T. Tahara, H. Ohashi, K. Ogami, T. Kato, et al.
Functional Analysis of the C-terminal Region of Recombinant Human Thrombopoietin. C-TERMINAL REGION OF THROMBOPOIETIN IS A "SHUTTLE" PEPTIDE TO HELP SECRETION
J. Biol. Chem.,
April 14, 2000;
275(16):
12090 - 12094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sakamaki, Y. Hirayama, T. Matsunaga, H. Kuroda, T. Kusakabe, T. Akiyama, Y. Konuma, K. Sasaki, N. Tsuji, T. Okamoto, et al.
Transforming Growth Factor-beta 1 (TGF-beta 1) Induces Thrombopoietin From Bone Marrow Stromal Cells, Which Stimulates the Expression of TGF-beta Receptor on Megakaryocytes and, in Turn, Renders Them Susceptible to Suppression by TGF-beta Itself With High Specificity
Blood,
September 15, 1999;
94(6):
1961 - 1970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Yagi, K. A. Ritchie, E. Sitnicka, C. Storey, G. J. Roth, and S. Bartelmez
Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin
PNAS,
July 6, 1999;
96(14):
8126 - 8131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Cohen-Solal, N. Vitrat, M. Titeux, W. Vainchenker, and F. Wendling
High-Level Expression of Mpl in Platelets and Megakaryocytes Is Independent of Thrombopoietin
Blood,
May 1, 1999;
93(9):
2859 - 2866.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
